<?xml version="1.0" ?>
<TimeML xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://timeml.org/timeMLdocs/TimeML_1.2.1.xsd">
<DOCID>695199597633</DOCID>
<DCT><TIMEX3 tid="t0" type="DATE" value="2017-01-29" temporalFunction="false" functionInDocument="CREATION_TIME">January 29, 2017</TIMEX3></DCT>
<TITLE>Julphar CEO Leaves the Company after 8 Years of Service</TITLE>
<TEXT>
Ras Al Khaimah, United Arab Emirates -Sunday, January 29th 2017 [ ME NewsWire ] 
 
Upon expiration of his contract – which comes in Q2 2017 – Dr Ayman Sahli , Chief Executive Officer of Julphar , has decided not to renew. The Board respects his wishes and has accepted his decision. Processes are underway to select his successor. 
 
Commenting on Dr Ayman’s decision, His Highness Sheikh Faisal Bin Saqr Al Qasimi , Chairman of Julphar, said: "We appreciate Dr Ayman’s outstanding service for more than eight years. Despite the challenging market conditions, Dr Ayman made a major contribution to Julphar and the company has achieved significant performance improvements and profitability under his leadership. On behalf of the Board, I sincerely wish him well for the future." 
 
"It has been a privilege to have had the opportunity to lead Julphar for the last decade and I am enormously proud of the accomplishments that have been made," said Dr Ayman Sahli. "The company has played such a positive role in my life. I am grateful for the support I have received from the Board of Directors and I express my heartfelt thanks to all employees for their dedication. I am confident that they will carry the company’s business forward to new heights." 
 
About Julphar 
 
Established in 1980, Julphar is the largest generic pharmaceutical manufacturer in Middle East and North Africa, producing over 200 branded products across its fifteen manufacturing facilities. Julphar’s mission is to offer high quality medicines at affordable prices, and its product portfolio includes: Wound, Anemia and Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care. In 2012 Julphar launched Julphar Diabetes, a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility that has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA). Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.47 billion in the year ending 2015. For more information, please visit http://www.julphar.net . 
   Contacts 
Mehtap Teke 
 
Corporate Communication Manager 
 
M +971-55-1934619, D +971-7-204-5209 
 
Tel +971-7-246-1461, FAX +971-7-246-2462,  mehtap.teke@julphar.net 
  
Permalink : http://www.me-newswire.net/news/3266/en
</TEXT>
</TimeML>
